Studies thinking speed in adults with sickle cell disease during transfusions
Observes how blood exchange transfusions affect thinking speed in adults with sickle cell disease.
Plain-language title generated from the registry record
Registry title: Transfusion Exchanges and Cognition in Sickle Cell Disease
Key facts
- Where
- Bobigny, Créteil, Le Kremlin-Bicêtre, Paris, and Saint-Denis, FranceSee the 6 sites
Where in France
- Assistance Publique Hôpitaux de Paris, Hôpital AvicenneBobigny, FranceNo longer taking part
- Hopital Henri MondorCréteil, FranceNo longer taking part
- Hôpital Kremlin-BicêtreLe Kremlin-Bicêtre, FranceNo longer taking part
- Assistance Publique - Hôpitaux de Paris Hôpital NeckerParis, FranceNo longer taking part
- GHU Paris Psychiatrie et Neurosciences - Hôpital Sainte-AnneParis, FranceNo longer taking part
- Centre Hospitalier Saint-DenisSaint-Denis, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier St Anne
- Trial code
- NCT07168447
- Record updated
- 11 September 2025
- Original description
DREPA-COG is an observational study evaluating the effect of exchange transfusions on cognitive function in adults with severe sickle cell disease (SS or Sβ0). Information processing speed is assessed at three time points during the transfusion cycle using the Symbol Digit Modalities Test (SDMT) and additional validated neuropsychological measures. This minimal-risk, fully remote study aims to identify processing speed as a reproducible marker for clinical monitoring and future therapeutic trials.Read full original descriptionShow less
Effect of Exchange Transfusions on Cognitive Efficiency in Patients With Sickle Cell Disease
DREPA-COG is an observational study evaluating the effect of exchange transfusions on cognitive function in adults with severe sickle cell disease (SS or Sβ0). Information processing speed is assessed at three time points during the transfusion cycle using the Symbol Digit Modalities Test (SDMT) and additional validated neuropsychological measures. This minimal-risk, fully remote study aims to identify processing speed as a reproducible marker for clinical monitoring and future therapeutic trials.
Inclusion: Adults (≥18 years) with severe sickle cell disease (SS or Sβ0); Enrolled in a regular monthly transfusion exchange program; Not institutionalized; No known dementia; No severe aphasia; Affiliated with or beneficiary of a social security system.
Exclusion: Known psychiatric disorders; Insufficient mastery of spoken French; Severe comorbidities preventing short-term follow-up; Participation in another clinical study with ongoing exclusion periods; Lack of adequate computer equipment (minimum 11-inch screen and internet connection); Vulnerable patients under legal protection (guardianship or curatorship).